TC BioPharm (Holdings) Ltd Stock Price, News & Analysis

TC Biopharm (NASDAQ: TCBP) announced that the UK regulatory body MHRA has approved an 18-month extrapolated shelf life for its allogeneic cell therapy product, OmnImmune®. This approval allows the company to store and ship the product for clinical trials and future patient treatments, enhancing operational efficiency and scaling. This milestone underscores TC Biopharm's commitment to advancing gamma-delta T cell therapies in oncology and positions OmnImmune® as a leading 'off-the-shelf' cell therapy. CEO Bryan Kobel highlighted this approval as a validation of the company's ongoing development efforts.

TC Biopharm (Holdings) PLC (NASDAQ: TCBP) announced that CEO Bryan Kobel will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 7:00 am. The company is focused on developing allogeneic gamma-delta T cell therapies for cancer treatment and is conducting pivotal clinical trials, including a Phase 2b/3 trial for OmnImmune® in acute myeloid leukemia. A webcast of the presentation will be available on TC BioPharm's Investor Relations page.

TC Biopharm, a clinical-stage biotechnology firm, will present at the 3rd Gamma Delta T Therapies Summit in Boston from July 26-28, 2022. Key executives, including Emilio Cosimo, Dr. Michael Leek, and Angela Scott, will lead multiple sessions covering gamma-delta T cell therapies for cancer. The summit is expected to gather over 120 leaders in the field, emphasizing TC Biopharm's position as a leader in gamma-delta T cell therapy development with ongoing clinical trials for cancer treatments.

TC BioPharm (NASDAQ: TCBP) will have its CEO, Bryan Kobel, participate in a fireside chat at the "Innovating Cell and Gene Therapy Quality Control Conference 2022" on July 13, 2022. The session, moderated by Caroline Peachey, will address TC BioPharm's growth as a cell and gene therapy startup, quality control challenges, and advice for industry peers. TC BioPharm focuses on developing gamma-delta T cell therapies, including its promising product OmnImmune®, which targets relapse/refractory Acute Myeloid Leukemia and has received positive trial feedback and orphan drug status from the FDA.

TC Biopharm (NASDAQ: TCBP) announced the closure of its underwritten public offering of 10 million American Depositary Shares (ADSs) at $0.40 each, generating gross proceeds of $4 million. The offering allows underwriters a 45-day option to purchase an additional 1.5 million ADSs. This funding is intended to support the development of gamma-delta T cell therapies for cancer. The company is recognized as a leader in this field and is conducting phase II/III clinical trials for its OmnImmune® treatment in acute myeloid leukemia.

TC BioPharm (NASDAQ: TCBP) has announced the pricing of a public offering involving 10 million American Depositary Shares (ADSs) at $0.40 each, totaling $4 million in gross proceeds. The offering is set to close around June 7, 2022, pending customary conditions. The underwriters have a 45-day option to purchase an additional 1.5 million ADSs. The company specializes in developing gamma-delta T cell therapies for cancer treatment, with ongoing clinical trials and a strong intellectual property portfolio.

TC Biopharm (NASDAQ: TCBP) announced a significant rise in acute myeloid leukemia (AML) diagnoses globally, increasing by 34.6% among men and 7.9% among women from 1990 to 2019, according to a recent study. In response, the Company highlighted the urgency for innovative cancer therapeutics, specifically its allogeneic gamma-delta T cell therapy, OmnImmune, currently in Phase 2B/3 trials. The FDA has granted Orphan Drug status to OmnImmune, with promising early results indicating low toxicity and potential effectiveness as a standalone and combination therapy. The Company aims to launch this treatment in 2023.

TC Biopharm (NASDAQ: TCBP) has been recognized by Kuick Research as a leading player in the gamma-delta T cell therapy market, projected to exceed $4 billion by 2028. The company is advancing its allogeneic gamma-delta T cell therapies, specifically with its OmnImmune® product, currently in a Phase 2b/3 trial for acute myeloid leukemia. Early trials showed a significant decrease in cancer levels from 38% to 6% without serious side effects. TC Biopharm’s operations and management position it well for growth in this promising sector.

TC Biopharm (NASDAQ: TCBP) announced the formation of a Scientific Advisory Board (SAB) to advance its gamma-delta T cell therapy, OmnImmune®, for Acute Myeloid Leukemia (AML). Dr. Mark Bonyhadi, with over 30 years in biopharmaceuticals, will lead the SAB alongside notable experts like Uma Lakshmipathy and Erin Adams. The SAB aims to bolster the company's research and development efforts in oncology. TC BioPharm is a leader in gamma-delta T cell therapies with ongoing phase II/III trials, demonstrating a commitment to innovation in the field of cancer treatment.